GlassScriptPhysician profile
Pradip Mishra
NPI 1679660096
$7,913.49
in general payments reported to CMS, 2019-2025
33 companies · $556 in 2025
The $556 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $547 · 2021: $735 · 2022: $2,256 · 2023: $1,183 · 2024: $1,557 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,297.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,403.43 | 2021-2024 | Micra, Plasmablade(Tm) |
| Boston Scientific Corporation | $1,032.07 | 2019-2025 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $899.44 | 2019-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $893.57 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $590.05 | 2019-2025 | Jardiance |
| Abbott Laboratories | $496.75 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Optisure |
| Astrazeneca Pharmaceuticals LP | $442.64 | 2019-2024 | Farxiga, Andexxa, Brilinta |
| Novartis Pharmaceuticals Corporation | $360.29 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $197.89 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $193.88 | 2019-2023 | |
| Pfizer INC. | $169.01 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $131.32 | 2019 | |
| Esperion Therapeutics, INC. | $109.86 | 2020-2024 | Nexletol |
| Abiomed | $109.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $108.94 | 2022-2025 | Eliquis, Camzyos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $108.20 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $98.35 | 2019-2025 | |
| Silk Road Medical, INC. | $92.57 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Novo Nordisk INC | $72.83 | 2024 | Rybelsus, Ozempic |
| Baxter Healthcare | $59.25 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Philips North America LLC | $58.71 | 2024-2025 | (Ck4) Mcot, Extended Holter |
| Alnylam Pharmaceuticals INC. | $55.78 | 2024 | Onpattro |
| Merck Sharp & Dohme LLC | $47.00 | 2022-2024 | Verquvo |
| Preventice Services, LLC | $43.59 | 2021 | |
| Scpharmaceuticals INC. | $19.32 | 2023 | |
| Daiichi Sankyo INC. | $19.18 | 2020 | |
| Janssen Biotech, INC. | $18.58 | 2025 | Tremfya |
| Cardiva Medical, INC. | $17.86 | 2019 | |
| Amarin Pharma, INC. | $17.75 | 2019 | |
| Lundbeck LLC | $14.60 | 2019 | |
| Medtronic Vascular, INC. | $12.75 | 2019 | |
| Elutia, INC. | $9.27 | 2019 | |
| Bardy Diagnostics, INC. | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradip Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.